The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 
      
  
LRRK2 Challenge, 2011Regulation of LRRK2 Activity by Nitric Oxide-Mediated Protein S-NitrosylationObjective/Rationale: 
 Mutations in the LRRK2 gene are a common cause of familial Parkinson’s disease (PD). Familial mutations can influence the GTPase or kinase activity of LRRK2 which may be...
- 
      
  
Rapid Response Innovation Awards, 2012Nigrostriatal Alpha-Synuclein Over-Expression in Young and Aged Pre-Clinical ModelsObjective/Rationale: 
 Accurate pre-clinical models of Parkinson’s disease are needed in order to test novel therapies as well as to further our understanding of the disease itself. The molecule alpha...
- 
      
  
MJFF Research Grant, 2012Generation of Phospho-Ser65 Parkin and Phospho-Thr257 PINK1 Pre-clinical Monoclonal Antibodies and Characterization of Total PINK1 Pre-clinical Monoclonal AntibodiesObjective/Rationale: 
 Mutations in an enzyme known as PINK1 can cause Parkinson’s disease. There has been
 great interest in understanding the function of PINK1 since uncovering the pathways that
 PINK1 is...
- 
      
  
MJFF Research Grant, 2012Design of HdAd Type 5 LRRK2 Expression VectorsObjective/Rationale: 
 LRRK2 is a gene that is has been implicated in Parkinson’s disease. LRRK2 is a large cDNA of approximately 7.6 kb that precludes it from being expressed in viral vectors such as...
- 
      
  
Therapeutics Development Initiative, 2012Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s DiseaseObjective/Rationale: 
 Fumaric acid esters have shown immuno-modulatory and neuroprotective effects in cell-based systems, pre-clinical models of disease and clinical trials in multiple sclerosis and...
- 
      
  
Clinical Intervention Awards, 2012Sublingually Administered APL-130277 Compared to Apokyn in Healthy VolunteersObjective/Rationale: 
 Apomorphine is an under-utilized medication in Parkinson's disease (PD). Despite its strong efficacy as a rescue medication for intermittent "off" episodes in PD and its rapid...
 
  Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.